Stop Waiting for Revenue to Build Your Brand w. Whit Slightham

Stop Waiting for Revenue to Build Your Brand w. Whit Slightham

Most founders think marketing can wait until they have a working prototype or need to raise money. By the time you need a pitch deck or professional website, it's already too late to do them well. Whit Slightham knows this from both sides. She's led communications for a multi-billion dollar biomedical research institute, founded Mesa Marketing to work with medtech startups, and she's currently living the founder journey herself. Her company Ateleva is developing a minimally invasive balloon catheter for treating lobar collapse in ICU patients. In this episode, Whit breaks down why checking trademark availability matters before you build brand equity, how to build a pitch deck that earns investor time in the first two minutes, and why you need three versions of your deck for different audiences. She also shares her own founder journey from April idea to filed patents and pitch competition wins, what it's like being on the other side pitching her own company, and why understanding your why is the only thing that gets you through the 3000-item to-do list. If you think you'll worry about branding once you're ready to raise money, this conversation will change your timeline. Timestamps: 00:05 - Introduction: Why marketing gets pushed to the bottom but shouldn't 02:05 - Starting with discovery: Who uses it, who approves it, who pays for it 03:30 - The trademark mistake most founders make before building brand equity 05:17 - Company names, DBAs, and brand kits: Why it matters early 07:26 - When founders wait too long: Reacting instead of leading the conversation 09:19 - Making your website look established without pretending to be 200 people 10:57 - Three marketing assets you need with no revenue: Brand kit, website, LinkedIn 13:37 - Why pitch decks take two and a half months when you think it'll be an hour 16:47 - You only get two minutes: How that reality shapes deck structure 18:45 - Three versions of your deck: Live presentations, leave behinds, appendix 22:11 - For the technical founder staring at blank slides: Start with a Word doc 23:23 - Ateleva's origin story: From April idea to filed patents in months 27:02 - Being on the other side: What it's like pitching your own company 28:59 - Peeling the onion: Every answer raises three new questions 30:34 - Regulatory pathways and de-risking as fast as possible 32:00 - If you knew what was ahead, would you still start? 35:33 - Rapid fire: Marketing assets, biggest mistakes, next two years Follow Melita and Whit: Connect with Melita:  LinkedIn: https://www.linkedin.com/in/melitaball/ Website: https://www.mbcaconsulting.com/about-us Connect with Whit:  LinkedIn: https://www.linkedin.com/in/whitneyslightham/ Website: https://mesamarketing.io/whitney-slightham/

Two Key Things That Make or Break Your Start Up w. Steve Duddy

There are precisely two things that will sink a medtech company: finance and regulatory. Get either one wrong and you're done. Steve Duddy has spent decades in the CEO chair learning this lesson the hard way. In this episode, Steve shares why regulatory strategy must start on day one, what happens when founders try to outsmart the FDA, and why the best regulatory teams are the ones who will tell a CEO no. You'll learn about breakthrough designation and why the bar isn't as high as most founders think, how to salvage a failed pre-submission meeting, and why talking to your board members individually before board meetings prevents disaster. Steve also breaks down the difference between clearance and approval, explains why fast and right are two different things, and shares his perspective on AI in medtech and where the FDA is headed. If you think regulatory strategy can wait until you have a working prototype, this conversation will change your timeline entirely. Timestamps: 00:04 - Introduction: Why regulatory is as critical as finance 02:00 - The costly mistake of pushing ahead without regulatory strategy 05:08 - Building FDA reputation: Why first impressions matter forever 07:32 - Coming to the regulatory table too late: A cautionary example 09:32 - Understanding the three main FDA pathways: 510(k), PMA, De Novo 12:40 - Breakthrough designation: Lower bar than most founders think 16:00 - Running pre-submissions in parallel with breakthrough applications 16:40 - What goes wrong when founders do pre-subs alone 19:48 - The language trap: Why words matter more than you think 22:28 - Predicate stacking: Taking bites of the elephant instead of swallowing it whole 23:32 - FDA uncertainty: What founders should know right now 26:00 - Compliance vs regulatory: Understanding the difference 29:00 - Quality systems and strategic acquisitions: Why strategics care now 31:40 - What makes a top-notch regulatory team 35:24 - Fast vs right: Maintaining regulatory integrity under pressure 38:12 - Board management: The one-off conversation strategy 39:36 - Commercialization: Why salespeople will make up their own words 44:40 - AI in medtech: Flying the plane while building it 47:56 - Rapid fire: First 90 days, biggest mistakes, FDA predictions Follow Melita and Steve: Connect with Melita:  LinkedIn: https://www.linkedin.com/in/melitaball/ Website: https://www.linkedin.com/in/melitaball/ Connect with Steve:  LinkedIn: https://www.linkedin.com/in/steveduddy Website: https://duddyexecutiveservices.com/

Commercial Success Beyond Regulatory Clearance w. Robert Hamilton

FDA clearance used to feel like the finish line. Robert Hamilton thought so too when he founded NeuraSignal. Then he learned the hard way that regulatory approval is just the beginning. In this episode, Robert shares the journey from developing the world's first fully automated robotic system for cerebral blood flow monitoring to building a commercially successful medtech company with operations in both the US and Canada. You'll hear about the pivot from traumatic brain injury to ischemic stroke when reimbursement pathways didn't align, why expanding internationally too early cost hundreds of thousands of dollars, and how clinical trial site selection can make or break your timeline and budget. Robert breaks down the three-legged stool every founder needs (regulatory, clinical, reimbursement), why usability testing is not a checkbox exercise, and how quality management systems evolve from compliance tools into competitive advantages. If you think getting through the FDA is the hard part, this conversation will recalibrate your expectations and strategy. Timestamps: 00:00 - Introduction: From UCLA ICU to commercializing breakthrough technology 03:00 - The accidental discovery that became Neuros Signal 05:00 - The three-legged stool: Regulatory, clinical, and reimbursement strategy 08:00 - Three company name changes: Lessons in trademarks and branding 10:00 - Why cerebral blood flow monitoring matters and the gap in the market 13:00 - Three times higher diagnostic rates: Real clinical impact stories 16:00 - When FDA clearance felt like the end (but was actually the beginning) 19:00 - Usability testing beyond regulatory checkboxes 22:00 - Fundraising realities: Structure matters as much as valuation 25:00 - The strategic approach to multiple 510(k) submissions 28:00 - Quality management systems: From compliance burden to competitive advantage 33:00 - Most expensive mistakes: International expansion and clinical trial site selection 36:00 - Why reimbursement work takes most of your time post-clearance 39:00 - Rapid fire: Post-FDA advice, regulatory strategy mistakes, resources Follow Melita and Robert: Connect with Melita:  LinkedIn: https://www.linkedin.com/in/melitaball/ Website: https://www.mbcaconsulting.com/ Connect with Robert:  LinkedIn: https://www.linkedin.com/in/hamiltonrobert/ [https://www.linkedin.com/in/hamiltonrobert/] Website: https://neurasignal.com/ [https://neurasignal.com/]

Why FDA Clearance Won’t Save Your Startup w. Cindy Grabowski

Getting FDA clearance used to be the finish line. Now it's just the starting gate. Cindy Grabowski has watched medtech acquisition timelines stretch from three years to eight-plus years across her 30-year career, and she knows exactly why the rules changed. In this episode, she breaks down the 2012 turning point when big medtech companies shifted their acquisition criteria from regulatory approval to predictable payment. You'll learn why reimbursement strategy must start on day one, how to design clinical trials that work globally, and what the five-publication requirement really means for Category 1 CPT codes. If you're a founder who thinks regulatory approval will get you acquired, this conversation will change your strategy. Timestamps: 00:00 - Introduction: The evolution of medtech acquisitions 02:00 - The 2004 shift: When big medtech changed their acquisition model 05:00 - The 2012 turning point: Predictable payment becomes the new bar 08:00 - Why FDA clearance is no longer the finish line 11:00 - Designing clinical studies with global data in mind 16:00 - How AI can accelerate protocol development 19:00 - AMA requirements for reimbursement and the five-publication rule 24:00 - The trap of "we only need enough data for regulatory approval" 29:00 - Four critical roles every founder must align from day one 33:00 - Mind Grove: Building cross-functional training for medtech professionals 36:00 - Rapid fire questions 40:00 - Where to connect with Cindy Follow Melita and Cindy: Connect with Melita:  LinkedIn: https://www.linkedin.com/in/melitaball/ [https://www.linkedin.com/in/melitaball/] Website: https://www.mbcaconsulting.com/ [https://www.mbcaconsulting.com/] Connect with Cindy:  LinkedIn: https://www.linkedin.com/in/cindy-grabowski/ [https://www.linkedin.com/in/cindy-grabowski/] Website: https://mindgrove.com/ [https://mindgrove.com/]

How Startups Actually Succeed w. Anita Bell

Most technical founders spend years perfecting their device, only to discover there's no market willing to pay for it. Anita Bell has seen this pattern repeat hundreds of times in her 20+ years as Director of the University of Arizona Center for Innovation.  In this episode, Anita shares the harsh realities technical founders face when they fall in love with their technology instead of their customers. From the handheld pump that was too big for nurses' hands (discovered only after FDA approval) to the critical differences between pitching for prizes versus real investor money, Anita reveals the systematic approach her incubator uses to help founders avoid expensive mistakes. She introduces UACI's 28-point roadmap that takes companies from idea to exit, explains why "I built it and they will come" thinking kills startups, and shares why the most expensive mistake has nothing to do with technology at all. Timestamps:  [00:00] Welcome and Anita's journey into incubation  [02:00] What makes startups succeed or fail  [03:25] The 28-point roadmap approach  [07:00] Technical founders versus business founders  [08:15] Why customer discovery is critical  [11:25] The handheld pump story: missing the obvious  [14:05] Guiding founders through customer discovery  [18:25] The "day in the life" methodology  [22:20] Pitching for prizes versus real investors  [28:20] Key elements of compelling MedTech pitches  [32:40] Building support networks without formal incubators  [36:45] International soft landing programs  [40:05] Rapid fire: advice, resources, and predictions Follow Melita and Anita: Connect with Melita:  LinkedIn: https://www.linkedin.com/in/melitaball Website: https://www.mbcaconsulting.com/about-us Connect with Anita:  LinkedIn: https://www.linkedin.com/in/bellanita/